BRIEF-Gilead COO says slowdown in patients starting hep C therapies to continue in 2017

* Gilead exec says slowdown in patients starting hepatitis c therapies to continue in 2017
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.